- $525.08m
- $228.05m
- $0.04m
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Boehringer-Zealand's obesity drug shows promise in cutting visceral, liver fat
U.S. RESEARCH ROUNDUP-Costco Wholesale, HCA Healthcare, Micron Technology
Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial (updated)
Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial
U.S. STOCKS ON THE MOVE- Lululemon, United Rentals, cannabis stocks
U.S. STOCKS ON THE MOVE- American Airlines, Pot stocks, Paramount Skydance
U.S. STOCKS ON THE MOVE-IBM, American Airlines, Texas Instruments
U.S. STOCKS ON THE MOVE-Honeywell, Netflix, CSX
Altimmune tumbles on $225 mln equity raise for liver disease drug
Brief: Altimmune Announces Proposed Underwritten Public Offering Of Securities
Altimmune tumbles on planned stock offering to fund liver disease drug
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Lilly gains after FDA approves weight-loss pill, sizing down investor doubts
Eli Lilly rises after US FDA approves weight-loss pill
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
U.S. STOCKS ON THE MOVE -Erasca Inc, Regenxbio, Natgas stocks
Altimmune falls after posting quarterly revenue below estimates
Altimmune Q4 revenue beats, EPS misses estimates